International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19
International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19
复制标题
DOI：
10.1016/j.jcyt.2020.05.002
复制
发表时间：
2020-09-01
期刊：
影响因子：
4.5
通讯作者：
Giebel, Bernd
中科院分区：
文献类型：
--
作者：
Boerger, Verena;Weiss, Daniel J.;Giebel, Bernd
声明：国际细胞与基因治疗学会和国际细胞外小泡学会认识到来自间充质基质细胞(MSCs)和可能的其他细胞来源的细胞外小泡(EV，包括外体)作为新冠肺炎治疗的潜力。鼓励在这一领域进行研究和试验。然而，ISEV和ISCT目前不支持将EVS或Exosome用于新冠肺炎的任何目的，包括但不限于减少细胞因子风暴、发挥再生效应或递送药物，直到产生适当的制造和质量控制规定、临床前的安全性和疗效数据、合理的临床试验设计和适当的监管监督。(C)2020年国际细胞和基因治疗学会。这是一篇CC BY-NC-ND许可证下的开放获取文章。(http://creativecommons.org/licenses/by-nc-nd/4.0/)
STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight. (C) 2020 International Society for Cell and Gene Therapy. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)